Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675960 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
A Phase 2 study, sponsored by Gillette Children's Specialty Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01675960 is a Phase 2 study that was terminated before completion, run by Gillette Children's Specialty Healthcare. The registered enrollment target is 2 participants.
The verdict
NCT01675960, a Phase 2 study, was terminated before completion, sponsored by Gillette Children's Specialty Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources.
Interventions
- DRUG placebo
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675960
The ClinicalTrials.gov registry entry for NCT01675960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gillette Children's Specialty Healthcare, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01675960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675960 about?
NCT01675960 is a clinical study titled "Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children". This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children wit...
What is the current status of trial NCT01675960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01675960?
The interventions under investigation include: placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT01675960?
This trial is sponsored by Gillette Children's Specialty Healthcare, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.